Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report
Semlitsch T, Ciutan M, Scintee SG
Record ID 32018000338
Authors' objectives: Coronary artery disease (CAD) is a disease defined as the manifestation of arteriosclerosis in the coronary arteries and is the leading cause of death in Europe. This systematic review evaluates the current evidence on the efficacy and safety of bioresorbable stents, the latest generation of stents in percutaneous coronary intervention (PCI) in the treatment of CAD, compared to traditional revascularisation strategies (PCI with permanent metal stents or coronary artery bypass graft surgery).
Authors' results and conclusions: Based on evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent Absorb® BVS is considered to be less effective and to have a worse safety profile compared with everolimus- or biolimus-eluting permanent metal stents. There is insufficient evidence to determine whether Absorb® BVS is considered less effective or less safe than other revascularisation strategies. There is also insufficient evidence to determine whether the other four currently CE-certificated fully bioresorbable stent systems (DESolve®, Magmaris [Dreams 2G], Art Pure or Fantom®) are more effective than (or at least as effective as) and/or have better (or at least similar) safety profiles compared with drug-eluting permanent metal stents or other revascularisation strategies.
Project Status: Completed
URL for project: https://aihta.at/page/homepage/null/page/4
Year Published: 2019
URL for published report: http://eprints.aihta.at/1191/1/DSD_81_Update2019.pdf
URL for additional information: http://eprints.aihta.at/1191/
English language abstract: An English language summary is available
Publication Type: Full HTA
- Surgical Procedures, Operative
- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Coronary artery disease (CAD)
- bioresorbable stents (BRS)
- percutaneous coronary intervention (PCI)
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.